Why Cancer-Fighting Stocks & ETFs Are Soaring

ETF Spotlight

English - June 03, 2019 16:18 - 30 minutes - 70.4 MB - ★★★★★ - 66 ratings
Investing Business Education investing business etfs exchangedtradedfunds Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Marijuana Stocks & ETFs: What Investors Need to Know

Next Episode: Should You Buy India ETFs after Modi’s Re-Election?

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

(1:00) - What Can Investors Learn From the ASCO Annual Meeting?

(5:45) - What Is Immunotherapy and What Are The Benefits?

(12:15) - What Companies Are Leading The Way?

(17:50) - AstraZeneca's Early Stage Cancer Treatments

(21:00) - Recent Merger and Acquisitions For Biopharmaceutical Industry

(23:25) - Loncar Cancer Immunotherapy ETF: CNCR

(26:40) - Policy Concerns Impacting The Healthcare Sector [email protected]